Aldeyra Therapeutics Reports $9.8 Million Net Loss in Q2 2025, 42% Improvement Year-Over-Year

Aldeyra Therapeutics, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $9.8 million, a significant reduction from the $16.8 million loss recorded in the same period of 2024. This represents a 42% improvement year-over-year. For the first half of 2025, the company reported a net loss of $19.7 million, down from $24.9 million in the first half of 2024, marking a 21% decrease. The company's total revenue for the quarter was not specified, but the reduction in losses was attributed to decreased operating expenses, particularly in research and development, which fell to $8.5 million from $15.0 million in the prior year.

The company’s total assets decreased to $84.9 million as of June 30, 2025, down from $104.6 million at the end of 2024. This decline was primarily due to a reduction in cash and cash equivalents, which fell to $41.2 million from $54.5 million. Aldeyra's total liabilities also decreased, amounting to $29.7 million compared to $33.6 million at the end of the previous fiscal year. The company’s stockholders' equity was reported at $55.3 million, down from $71.0 million at the end of 2024, largely due to accumulated losses.

In terms of strategic developments, Aldeyra has been focusing on its product pipeline, particularly the late-stage candidate reproxalap, which is being developed for dry eye disease. The company entered into an exclusive option agreement with AbbVie in October 2023, which allows AbbVie to potentially collaborate on the development and commercialization of reproxalap. As of June 30, 2025, AbbVie had not yet exercised this option. The agreement includes a $100 million upfront payment upon execution of the collaboration agreement, along with potential milestone payments totaling approximately $300 million.

Operationally, Aldeyra has seen a decrease in its employee headcount, which is reflected in the reduced general and administrative expenses, which fell to $1.7 million from $3.0 million year-over-year. The company continues to manage its cash flow carefully, with net cash used in operating activities decreasing to $21.0 million for the first half of 2025, compared to $23.2 million in the same period of 2024. The company also reported net cash provided by investing activities of $6.7 million, a turnaround from the $48.6 million used in the prior year, primarily due to maturities of marketable securities.

Looking ahead, Aldeyra anticipates that its cash, cash equivalents, and marketable securities will be sufficient to fund its projected operating expenses and debt obligations into 2027. However, the company acknowledges the need for additional funding to support ongoing research and development activities, regulatory requirements, and potential commercialization efforts. The company remains focused on advancing its product candidates while navigating the complexities of the biotechnology landscape.